Lupin to sell Onset's pediatric brand in US

Agreement grants Lupin exclusive rights to promote Onset's Locoid Lotion to pediatricians in US

Lupin Pharmaceuticals Inc., US subsidiary of Lupin Ltd, has signed a strategic co-promotion agreement with US-based Onset Dermatologics, LLC that grants Lupin exclusive rights to promote Onset’s Locoid Lotion (hydrocortisone butyrate 0.1%) to pediatricians in the US. 

 

Locoid Lotion is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients of 3 months of age and older. Atopic Dermatitis (AD) is one of the most common skin disorders in young children and has a prevalence of 10 to 20% in the first decade of life. It is a chronic illness that requires a multifaceted treatment strategy in the setting of limited therapeutic options, said a company statement.

 

AD, more commonly called eczema, now affects 10 to 20% of children in the United States and direct health-care costs exceed $3 billion, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Locoid Lotion currently participates in a market that includes 17% of school-age children in the US between the ages of 5 – 7 years which is about 9.2 million children.

 

Lupin's product portfolio for the US pediatrics segment consists of Suprax and Alinia for Oral Suspension.